Literature DB >> 12727849

Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch.

Lev M Fedorov1, Thomas Papadopoulos, Oleg Y Tyrsin, Thomas Twardzik, Rudolf Götz, Ulf R Rapp.   

Abstract

One of the most frequent malignancies in humans is lung adenocarcinoma.To develop novel diagnostic and therapeutic approaches for the management of this disease, animal models are required. We have used transgenic mice with lung-targeted expression of the CRaf kinase to evaluate genes altered frequently in human lung adenocarcinoma for their effect on tumor progression. Here we report that loss of p53 dramatically accelerates tumor development and induces a phenotypic switch in the target cell from cuboid to a nonciliated columnar morphology. Coexpression of lung epithelial cell markers surfactant protein C and Clara cell antigen suggests that tumor cell dedifferentiation could be involved in this process. The effect of p53 is specific, because loss of one of its target genes, p21(CIP1/WAF1), did not have this effect on cell phenotype although tumor latency was also reduced significantly. Neither loss of p53 nor p21 stimulated acquisition of the metastasis program beyond the stage of bronchiolar extension. This mouse model for pulmonary adenoma and adenocarcinoma should be very helpful for a better understanding of pathogenesis and treatment of this most deadly human cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727849

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

2.  Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Authors:  Yingmei Wang; Da Yang; David Cogdell; Limei Hu; Fengxia Xue; Russell Broaddus; Wei Zhang
Journal:  Technol Cancer Res Treat       Date:  2010-04

3.  Apoptotic signaling proteins: possible participation in the regulation of vasopressin and catecholamines biosynthesis in the hypothalamus.

Authors:  Elena V Chernigovskaya; Andrey G Taranukhin; Margarita V Glazova; Liubov A Yamova; Lev M Fedorov
Journal:  Histochem Cell Biol       Date:  2005-08-25       Impact factor: 4.304

4.  MEK-1 activates C-Raf through a Ras-independent mechanism.

Authors:  Deborah T Leicht; Vitaly Balan; Jun Zhu; Alexander Kaplun; Agnieszka Bronisz; Ajay Rana; Guri Tzivion
Journal:  Biochim Biophys Acta       Date:  2013-01-27

5.  MYC is a metastasis gene for non-small-cell lung cancer.

Authors:  Ulf R Rapp; Christian Korn; Fatih Ceteci; Christiaan Karreman; Katharina Luetkenhaus; Valentina Serafin; Emanuele Zanucco; Inês Castro; Tamara Potapenko
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

6.  Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancer.

Authors:  Matthias Becker; Christian Korn; Arnold R Sienerth; Robert Voswinckel; Katharina Luetkenhaus; Fatih Ceteci; Ulf R Rapp
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

7.  Premalignant lesions as targets for cancer vaccines.

Authors:  Olivera J Finn
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

8.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26

9.  Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.

Authors:  Boris W Kramer; Rudolf Götz; Ulf R Rapp
Journal:  BMC Cancer       Date:  2004-06-01       Impact factor: 4.430

10.  Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression.

Authors:  Rudolf Götz
Journal:  Cancer Cell Int       Date:  2008-05-20       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.